Please delete the abstract as originally filed on pages 329-331.

Please replace with the following:

ABSTRACT OF THE DISCLOSURE

A compound of formula I:



I

~~where a is a single bond or double bond, and where~~

~~R1a, R1b, R2a and R2b are each independently~~

~~(a) H, Cl, Br, I, F, CN, CF_3, OCF_3, OR5, CONR5R6, COR5, CO2R5, $Y(CH_2)_mXR5$ or $YC(O)(CH_2)_mXR5$, where m = 0-3, Y = CH_2, S, O, or NR6, X = CH_2, S, O, NR6;~~

~~(b) $(CH2)_pAr$ where p = 0-3 and Ar is aryl or heteroaryl optionally substituted with one or more of the following: H, halogen, CN, NO_2, OR7, CF_3, OCF_3, SR7, SO_2R7, SO_2NR7R8, NR7R8, CONR7R8, NR7COR8, NR7CONR8R9, CO_2R7, COR7, or R7; or~~

~~(c) linear or branched C_1-C_8 alkyl, linear or branched C_2-C_8 alkenyl, linear or branched C_2-C_8 alkynyl, C_3-C_8 cycloalkyl, C_3-C_8 cycloalkenyl, or C_3-C_8 cycloalkynyl; wherein any of these groups may be optionally substituted with one or more of the following:halogen, CN, NO_2, COR7, OR7, NR7R8, SR7, CO2R7, CONR7R8 or NR7COR8; and where~~

~~R3 is~~

~~(a) H, Cl, Br, I, F, CN, CF_3, OCF_3, alkyl, Ar, OR5, SR5, CHO, CONR5R6, COR5, CO2R5, (Y)$_q$(CH2)$_r$XR5, C(O)C(O)XR5, (Y)$_q$(CH$_2$)$_r$C(O)XR5, C(O)(CH2)$_r$XR5,~~

BEST AVAILABLE COPY

~~$(Y)_o(CH2)_nN(R6)C(O)R5$, $(Y)_o(CH2)_nN(R6)S(O)_2R5$, $(Y)_o(CH2)_nN(R6)C(O)OR5$, $(Y)_o(CH2)_nN(R6)C(O)NR5R6$ where o = 0 or 1, n = 0-3, X = CH_2, S, O, or NR6 and Y=CH_2, S, O or NR6, where Ar is aryl or heteroaryl optionally substituted with one or more of the following: H, halogen, CN, NO_2, OR7, CF_3, OCF_3, SR7, SO_2R7, SO_2NR7R8, NR7R8, CONR7R8, NR7COR8, NR7CONR8R9, CO_2R7, COR7, or R7; or~~

~~(b) linear or branched C_1-C_8 alkyl, linear or branched C_2-C_8 alkenyl, linear or branched C_2-C_8 alkynyl, C_3-C_8 cycloalkyl, C_3-C_8 cycloalkenyl, or C_3-C_8 cycloalkynyl; wherein any of these groups may be optionally substituted with one or more of the following: halogen, CN, NO_2, COR10, OR10, NR10R8, SR10, CO2R10, CONR10R8 or NR10COR8; and where~~

~~R4, R5 and R6 are each independently~~

~~(a) H, linear or branched C_1-C_8 alkyl, linear or branched C_2-C_8 alkenyl, linear or branched C_2-C_8 alkynyl, C_3-C_8 cycloalkyl, C_3-C_8 cycloalkenyl, or C_3-C_8 cycloalkynyl; wherein any of these groups other than H may be optionally substituted with one or more of the following: halogen, CN, NO_2, COR10, OR10, NR10R11, SR10, CO2R10, CONR10R11 or NR10COR11; or where R5 and R6 are linked to form a 3 to 8 member ring; or~~

~~(b) $(CH_2)_pAr$ where p = 0-3 and Ar is aryl or heteroaryl optionally substituted with one or more of the following: H, halogen, CN, NO_2, OR7, CF_3, OCF_3, SR7, SO_2R7, SO_2NR7R8, NR7R8, CONR7R8, NR7COR8, NR7CONR8R9, CO_2R7, COR7, or R7; and where~~

~~R7, R8, and R9 are each independently~~

~~(a) H, linear or branched C_1-C_8 alkyl, linear or branched C_2-C_8 alkenyl, linear or branched C_2-C_8 alkynyl, C_3-C_8 cycloalkyl, C_3-C_8 cycloalkenyl, or C_3-C_8 cycloalkynyl groups, wherein any of these groups other than H may be optionally substituted with halogen, CN, NO_2, COR10, OR10, NR10R11, SR10, CO2R10, CONR10R11,~~

~~NR10COR11, NR10CONR11R12, or where R7, R8, or R9 are linked to form a ring; or~~

~~(b) $(CH2)_p$Ar where p = 0-3 and Ar is aryl or heteroaryl optionally substituted with one or more of the following: H, halogen, CN, NO_2, OR10, CF_3, OCF_3, SR10, SO_2R10, SO_2NR10R11, NR10R11, CONR10R11, NR10COR11, NR10CONR11R12, CO_2R10, COR10, or R10; and where~~

~~R10, R11 and R12 are each independently H, linear or branched C_1-C_8 alkyl, linear or branched C_2-C_8 alkenyl, linear or branched C_2-C_8 alkynyl, C_3-C_8 cycloalkyl, C_3-C_8 cycloalkenyl, or C_3-C_8 cycloalkynyl;~~

~~or a stereoisomer or pharmaceutically acceptable salt thereof.~~

wherein a, R1a, R1b, R2a, R2b, R3, R4, R5, R6, R7, R8, R9, R10, R11, and R12 each have any of the definitions provided herein. The present invention provides novel diazepinoindole compounds of Formula I. These compounds are 5-HT ligands and are useful for treating diseases wherein modulation of 5-HT activity is desired.

This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☑ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.
As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.